MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

(2019) Hui Li et al.   GASTROENTEROLOGY

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

(2019) Valentina Martin et al.   BRITISH JOURNAL OF CANCER

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer

(2018) Maria Saigi et al.   CLINICAL CANCER RESEARCH

MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

(2018) Henning Reis et al.   Clinical Lung Cancer

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

(2018) Jean-David Fumet et al.   BRITISH JOURNAL OF CANCER

Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer

(2018) Arsela Prelaj et al.   EUROPEAN JOURNAL OF CANCER

MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics

(2017) Dohee Kwon et al.   LUNG CANCER

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment

(2017) Christina Demuth et al.   Oncotarget

Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients

(2017) Xiaofang Xing et al.   OncoImmunology

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

(2016) J. H. Tong et al.   CLINICAL CANCER RESEARCH

Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non–Small-Cell Lung Cancer

(2016) Jae Joon Han et al.   Clinical Lung Cancer

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

(2016) Mark M. Awad et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

(2016) Xuewen Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status

(2015) Su-Jin Shin et al.   ANNALS OF SURGICAL ONCOLOGY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers

(2015) Moon-Young Kim et al.   LUNG CANCER

Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status

(2015) Jaemoon Koh et al.   MODERN PATHOLOGY

EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3

(2015) Jaemoon Koh et al.   OncoImmunology

MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung

(2014) H.-U. Schildhaus et al.   CLINICAL CANCER RESEARCH

The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance

(2014) Christiane R. Maroun et al.   PHARMACOLOGY & THERAPEUTICS

Targeting the MET gene for the treatment of non-small-cell lung cancer

(2013) F. Gelsomino et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology